文献速递肝病消化道肿瘤与早癌

代谢功能障碍相关脂肪性肝病:一种伴随心血管和恶性肿瘤并发症的系统性代谢紊乱

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.
PubMed 文献 · Gut · 2024-03-07

非酒精性脂肪性肝病(NAFLD)全球成人患病率估计高达38%,2023年三大国际肝病学会提议以代谢功能障碍相关脂肪性肝病(MASLD)取代NAFLD,约99%的NAFLD患者符合MASLD标准。本文综述MASLD与心血管疾病及恶性肿瘤并发症的流行病学、机制及心血管风险评估与治疗。

要点

  • MASLD是伴系统性胰岛素抵抗的多系统疾病,可增加心血管疾病和肝外恶性肿瘤风险。
  • 2023年三大国际肝病学会提议以MASLD替代NAFLD,约99%的NAFLD患者符合MASLD标准。
  • 综述涵盖MASLD心血管及恶性肿瘤并发症的流行病学、机制及心血管风险评估与治疗。

核心结论

  • MASLD是一种系统性代谢紊乱,与心血管疾病和某些肝外恶性肿瘤等并发症相关。

研究设计与样本

  • 叙述性综述,总结MASLD流行病学、心血管及恶性肿瘤并发症风险、机制及心血管风险评估与治疗文献。

主要发现

  • NAFLD全球成人患病率估计高达38%。
  • 约99%的NAFLD患者符合MASLD标准。
  • 系统性胰岛素抵抗及相关代谢功能障碍在MASLD及其肝硬化、肝衰竭、肝细胞癌和心血管疾病、2型糖尿病、慢性肾脏病及某些肝外癌症的发生中起致病作用。

关键数值与推荐

  • 2023年三大跨国肝病学会提议以MASLD替代NAFLD,以代谢功能障碍相关脂肪性肝炎(MASH)替代非酒精性脂肪性肝炎。
  • 约99%的NAFLD患者符合MASLD标准。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Non-alcoholic fatty liver disease (NAFLD) has rapidly become the most common chronic liver disease globally and is currently estimated to affect up to 38% of the global adult population. NAFLD is a multisystem disease where systemic insulin resistance and related metabolic dysfunction play a pathogenic role in the development of NAFLD and its most relevant liver-related morbidities (cirrhosis, liver failure and hepatocellular carcinoma) and extrahepatic complications, such as cardiovascular disease (CVD), type 2 diabetes mellitus, chronic kidney disease, and certain types of extrahepatic cancers. In 2023, three large multinational liver associations proposed that metabolic dysfunction-associated steatotic liver disease (MASLD) should replace the term NAFLD; the name chosen to replace non-alcoholic steatohepatitis was metabolic dysfunction-associated steatohepatitis (MASH). Emerging epidemiological evidence suggests an excellent concordance rate between NAFLD and MASLD definitions-that is, ~99% of individuals with NAFLD meet MASLD criteria. In this narrative review, we provide an overview of the literature on (a) the recent epidemiological data on MASLD and the risk of developing CVD and malignant complications, (b) the underlying mechanisms by which MASLD (and factors strongly linked with MASLD) may increase the risk of these extrahepatic complications and (c) the diagnosis and assessment of CVD risk and potential treatments to reduce CVD risk in people with MASLD or MASH.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Targher G, Byrne CD, Tilg H, et al. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut. 2024. PMID: 38228377. doi:10.1136/gutjnl-2023-330595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。